Patents for A61P 35 - Antineoplastic agents (221,099)
06/2010
06/24/2010WO2010069441A1 3-(3-pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyrimidine derivatives
06/24/2010WO2010069074A1 Membrane type-1 matrix metalloprotein inhibitors and uses thereof
06/24/2010WO2010069054A1 Novel c-1analogs of pancratistatin and 7-deoxypancratistatin and processes for their preparation
06/24/2010WO2010051127A9 Hematopoietic protection against ionizing radiation using selective cyclin-dependent kinase 4/6 inhibitors
06/24/2010WO2010037856A3 DYNACTIN-1/p150glued AS A TARGET FOR TUMOR DIAGNOSIS AND THERAPY AND A METHOD FOR IDENTIFYING TARGETABLE DISEASE-RELATED PROTEINS
06/24/2010WO2010028156A3 Dual modality detection of apoptosis
06/24/2010WO2010025324A3 Nanoparticles for immunotherapy
06/24/2010WO2010010112A3 Construct and method for the internalization of cargo molecules into a cell
06/24/2010WO2010005958A3 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
06/24/2010WO2009155527A3 Phosphatidylinositol 3 kinase inhibitors
06/24/2010WO2009098454A3 Treatment of diseases and conditions mediated by eicosanoids
06/24/2010WO2007095223A3 Pyrrolo(3,2-c) pyridines useful as inhibitors of protein kinases
06/24/2010US20100162416 Multi-stage stem cell carcinogenesis
06/24/2010US20100160442 Formulations for cancer treatment
06/24/2010US20100160426 Crystalline genistein sodium salt dihydrate
06/24/2010US20100160409 Highly Branched Reagents For Modifying Biopharmaceuticals, Their Preparation And Use
06/24/2010US20100160405 Methods of using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline 1,3-dione
06/24/2010US20100160393 Crystal form of epothilone b and use in pharmaceutical compositions
06/24/2010US20100160392 Histone deacetylase inhibitors
06/24/2010US20100160381 RAF Inhibitors for the Treatment of Thyroid Cancer
06/24/2010US20100160372 Treatment of proteinopathies using a farnesyl transferase inhibitor
06/24/2010US20100160368 Methods of Treating Dermatological Disorders and Inducing Interferon Biosynthesis With Shorter Durations of Imiquimod Therapy
06/24/2010US20100160365 Treatment of non-hodgkin's lymphomas with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin
06/24/2010US20100160356 Novel cyclobutyl compounds as kinase inhibitors
06/24/2010US20100160350 Pyrazolopyrimidinone kinase inhibitor
06/24/2010US20100160349 Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors
06/24/2010US20100160343 Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by vla-4
06/24/2010US20100160341 Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by vla-4
06/24/2010US20100160340 Protein kinase inhibitors
06/24/2010US20100160338 Benzenesulfonamide modulators of alpha-1a adrenergic receptors
06/24/2010US20100160328 New compounds useful for dpp-iv enzyme inhibition
06/24/2010US20100160327 Modified Malonate Derivatives
06/24/2010US20100160325 4-(3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer
06/24/2010US20100160324 Pyrazole derivatives as that modulate the activity of cdk, gsk and aurora kinases
06/24/2010US20100160322 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
06/24/2010US20100160321 Imidazolinone and hydantoine derivatives as novel inhibitors of histone deacetylase
06/24/2010US20100160318 3-Pyrrolo[b]Cyclohexylene-2-Dihydroindolinone Derivatives and Uses Thereof
06/24/2010US20100160317 2-(2-oxoindoline-3-ylidene)methyl-5-(2-hydroxy-3-morpholin-4-yl-propyl)-6,7-dihydro-1h-pyrrol[3,2-c]pyridine-4(5h)-one compounds and use as protein kinase inhibitors
06/24/2010US20100160313 Discovery of novel anticancer compounds based on conformational sampling of quinoxalinhydrazide pharmacophore
06/24/2010US20100160309 Inhibitors of janus kinases and/or 3-phosphoinositide-dependent protein kinase-1
06/24/2010US20100160308 Thiazolyl-Benzimidazoles
06/24/2010US20100160297 Compounds for pim kinase inhibition and for treating malignancy
06/24/2010US20100160296 Use of imipramine blue and analogs thereof in treating cancers
06/24/2010US20100160287 Compounds useful as inhibitors of janus kinases
06/24/2010US20100160283 Heteroaryl-substituted alkyne compounds and method of use
06/24/2010US20100160275 Methods and compositions for cancer prevention and treatment
06/24/2010US20100160268 Isoflavonoid Analogs and their Metal Conjugates as Anti-Cancer Agents
06/24/2010US20100160261 Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof
06/24/2010US20100160257 Use of hdac inhibitors for the treatment of myeloma
06/24/2010US20100160246 Microspheres for treatment of brain tumors
06/24/2010US20100160241 Novel compound having gpr54 agonistic activity
06/24/2010US20100160239 Peptide nucleic acid based guanidinium compounds
06/24/2010US20100160238 TGFP-CAP Peptide and its Uses
06/24/2010US20100160234 Cell-proliferation inhibiting vpg proteins, fragments or analogs thereof and their applications
06/24/2010US20100160228 Method for inhibiting or stimulating angiogenesis in an individual
06/24/2010US20100160221 Effect of tula on hiv
06/24/2010US20100160220 Compositions and Methods for Improving Bone Mass Through Modulation of Novel Receptors of PTH and Fragments Thereof
06/24/2010US20100160210 Guanidinium delivery carriers
06/24/2010US20100159453 Genes involved in intestinal inflammatory diseases and use thereof
06/24/2010US20100159034 Pyrrolidinone inhibitors of pde-4
06/24/2010US20100159030 Methods for detecting and modulating the sensitivity of tumor cells to anti-mitotic agents and for modulating turmorgenicity
06/24/2010US20100159021 Small Molecule Ligands of the Integrin RGD Recognition Site and Methods of Use
06/24/2010US20100159020 Polymeric micelles for drug delivery
06/24/2010US20100158995 Systems for delivery and release of angiotensin-(1-7)
06/24/2010US20100158990 Transdermal method and patch for corticosteroid administration
06/24/2010US20100158956 Multiple unit dosage form having a therapeutic agent in combination with a nutritional supplement
06/24/2010US20100158942 Attenuated negative strand viruses with altered interferon antagonist activity for use as vaccines and pharmaceuticals
06/24/2010US20100158934 Nucleic acid and corresponding protein entitled 161p2f10b useful in treatment and detection of cancer
06/24/2010US20100158926 Antibodies to erbb2
06/24/2010US20100158920 Fully human antibodies directed against the human insulin-like growth factor-1 receptor
06/24/2010US20100158918 Polypeptides and polynucleotides encoding same
06/24/2010US20100158917 Methods for diagnosing cancer and decreasing metastasis by cancer cells
06/24/2010US20100158914 Klotho beta
06/24/2010US20100158911 Compositions and Methods of Treating Disease with FGFR Fusion Proteins
06/24/2010US20100158910 Treatment of renal cell carcinoma with anti-cd70 antibody-drug conjugates
06/24/2010US20100158907 Connective tissue growth factor fragments and methods and uses thereof
06/24/2010US20100158906 Use of recombinant monoclonal antibody with specific binding activity for cell surface phosphorylated glycoprotein in diagnosis and treatment of immune, cell proliferative and inflammatory disorders
06/24/2010US20100158904 Treatment with anti-alpha2 integrin antibodies
06/24/2010US20100158902 Monoclonal antibodies against stromal derived factor-1 (sdf-1)
06/24/2010US20100158899 Protein formulation
06/24/2010US20100158896 Antibody that specifically binds hyaluronan synthase
06/24/2010US20100158894 Preventive or remedy for er-negative and her2-negative breast cancer and method of screening the same
06/24/2010US20100158884 Cascade
06/24/2010US20100158871 Sickled erythrocytes with antitumor molecules induce tumoricidal effects
06/24/2010US20100158858 Administration of carboline derivatives useful in the treatment of cancer and other diseases
06/24/2010US20100158857 Compositions and methods for the inhibition of endothelial nitric oxide synthase activity
06/24/2010US20100158856 Assays and methods using biomarkers
06/24/2010US20100158843 Novel 3-phenylpropanoic compound activators of receptors of ppar type and pharmaceutical/cosmetic compositions comprised thereof
06/24/2010US20100158817 T1 mri trackable drug delivery particles, uses and methods thereof
06/24/2010US20100158814 Fibrin-Binding Peptides and Conjugates Thereof
06/24/2010US20100158812 Anti-Cancer Medicine Both for Diagnosing and Treating Cancer
06/24/2010US20100158802 antibody binds target tissue and conjugate carrying epitope (haptens); monoclonal antibody or fragment thereof binds to a colon-specific antigen-p mucin (CSAp) antigen - the Mu-9 epitope; DNA sequence; colon cancer
06/24/2010US20100158798 FP-Pocket-Binding Effectors and Methods for Using the Same to Modulate Telomerase Activity
06/24/2010DE102008063046A1 Medizinische Verwendung des ribosomalen Protein S19 (RPS19) Medical use of the ribosomal protein S19 (RPS19)
06/24/2010DE102008062825A1 3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo [4,3-b]pyridazin-derivate 3- (3-pyrimidin-2-yl-benzyl) - [1,2,4] triazolo [4,3-b] pyridazine derivatives
06/24/2010DE102008061247A1 Inhibitoren der Dimethylarginin Dimethylaminohydrolase Inhibitors of dimethylarginine dimethylaminohydrolase
06/24/2010CA2747565A1 Novel c-1analogs of pancratistatin and 7-deoxypancratistatin and processes for their preparation
06/24/2010CA2747287A1 3-(3-pyrimidin-2-ylbenzyl)-1,2,4-triazolo[4,3-b]pyrimidine derivatives
06/24/2010CA2747252A1 Pyrazine derivatives useful as inhibitors of atr kinase
06/24/2010CA2747220A1 Membrane type-1 matrix metalloprotein inhibitors and uses thereof